Safety and tolerability of long-term administration of dilaudid SR [slow release] (hydromorphone HCI) in cancer pain

Trial Profile

Safety and tolerability of long-term administration of dilaudid SR [slow release] (hydromorphone HCI) in cancer pain

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2009

At a glance

  • Drugs Hydromorphone (Primary)
  • Indications Cancer pain
  • Focus Therapeutic Use
  • Sponsors ALZA Corporation
  • Most Recent Events

    • 14 Jul 2009 Actual patient number (68) added as reported by ClinicalTrials.gov.
    • 14 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Jul 2009 Actual end date Apr 2002 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top